C

Cara Therapeutics
D

CARA

4.63000
USD
-0.07
(-1.49%)
Market Closed
Volume
3,209
EPS
-0
Div Yield
-
P/E
-0
Market Cap
21,165,082
OverviewSignalsIdeasNews
Related Instruments
    A
    ACB
    -0.04000
    (-1.03%)
    3.86000 USD
    C
    CGC
    0.00000
    (0.00%)
    2.22500 USD
    C
    CRBP
    -0.620
    (-5.18%)
    11.350 USD
    C
    CRON
    -0.02000
    (-1.03%)
    1.92000 USD
    T
    TLRY
    -0.04000
    (-3.40%)
    1.13500 USD
    More
News

Title: Cara Therapeutics Inc

Sector: Healthcare
Industry: Biotechnology
Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.